Spinal muscular atrophy: from tissue specificity to therapeutic strategies
Daniel M. Iascone1-4, Christopher E. Henderson*1-4 and Justin C. Lee1-4

Abstract
Spinal muscular atrophy (SMA) is the most frequent genetic cause of death in infants and toddlers. All cases of spinal muscular atrophy result from reductions in levels of the survival motor neuron (SMN) protein, and so SMN upregulation is a focus of many preclinical and clinical studies. We examine four issues that may be important in planning for therapeutic success. First, neuromuscular phenotypes in the SMNΔ7 mouse model closely match those in human patients but peripheral disease manifestations differ, suggesting that endpoints other than mouse lifespan may be more useful in predicting clinical outcome. Second, SMN plays important roles in multiple central and peripheral cell types, not just motor neurons, and it remains unclear which of these cell types need to be targeted therapeutically. Third, should SMN-restoration therapy not be effective in all patients, blocking molecular changes downstream of SMN reduction may confer significant benefit, making it important to evaluate therapeutic targets other than SMN. Lastly, for patients whose disease progression is slowed, but who retain significant motor dysfunction, additional approaches used to enhance regeneration of the neuromuscular system may be of value.

Introduction
SMA is the most frequent genetic cause of death in infants and toddlers. It was first described by Werdnig in 1891, when he observed two infant brothers with the onset of progressive proximal leg weakness at 10 months of age [1]. Hoffman, between 1893 and 1900, described an additional seven patients from three families [2–4]. Although these cases were of intermediate severity, Sylvestre in 1899 and Beevor in 1903 presented the first cases of severe SMA: two infants with flaccid paralysis of limbs and trunk muscles at birth [5–7]. These infants were from two families in which 7 out of 14 total children were affected, and all affected children died within 6 months of age. Over half a century later, Wohlfart, Eliasson, and Fex in 1955 and Kugelberg and Welander in 1956 described the mild ambulant form of SMA in two case series [7–9]. The clinical presentation was similar to a limb-girdle muscular dystrophy, but electromyography and a muscle biopsy documented neurogenic changes, leading to speculation that this represented a mild form of the disease described by Werdnig and Hoffman. Early descriptions of intermediate and severe forms of SMA all recognized a progressive and symmetric weakness involving the proximal extremities, axial muscles, and intercostal muscles, with prominent sparing of the diaphragm [7]. The accompanying pathological studies described degeneration of the motor neurons in the anterior horn of the spinal cord, the neurons through which the brain triggers contraction of skeletal muscle.

Despite this stereotyped pattern of neuromuscular weakness and motor neuron loss at autopsy, these early studies highlighted marked differences in age of onset, rate of progression, and overall severity of SMA. Thus, for over a century, it was unclear if SMA was one disease with a broad
spectrum of severity or represented multiple diseases. This spectrum of phenotypes was formally classified in 1991, based on the age of clinical onset and maximum motor function achieved [10]. Type I SMA, the most common subtype, is characterized by disease onset within 6 months of age and death within 2 years. The onset of Type II SMA occurs between 6 and 18 months of age, and patients gain the ability to sit upright but not walk. Type III SMA presents after 18 months of age and patients achieve ambulation, at least temporarily [10–15].

The fact that these are different manifestations of a single disease was demonstrated by the finding that 95% of all cases of SMA are caused by homozygous loss of the survival motor neuron 1 (SMN1) gene [16]. SMN is a ubiquitously expressed protein involved in multiple aspects of RNA metabolism, including RNA splicing. Complete loss of SMN would be embryonic lethal, but the absence of SMN1 is compensated for by variable copy numbers of the hypomorphic gene paralog survival motor neuron 2 (SMN2). SMN2 potentially encodes for the same protein as SMN1, but a single nucleotide transition in exon seven leads to the skipping of exon seven in the majority of transcripts, and production of a truncated SMN protein that is rapidly degraded [17–19]. On average, the higher the copy number of SMN2 the milder the phenotype, but copy number is not fully prognostic since SMN2 is not the sole disease modifier [20]. SMA has an incidence of approximately 1/11,000 live births and a pan-ethnic carrier frequency of 1/54 [21,22].

**Outstanding questions**

Human genetics and preclinical studies have provided clear proof of concept for SMN upregulation as a therapeutic strategy potentially applicable to all patients [23,24]. For this reason, clinical trials of several approaches using antisense oligonucleotides to correct the missplicing of SMN2, or viral vectors and small molecules to increase SMN levels, are underway or planned (Figure 1; [25]). This is, therefore, an exciting period for SMA therapeutics and the production of an attenuated SMA phenotype and death within 5 days, whereas eight copies of SMN2 essentially rescue the mice. The addition of an SMN transgene lacking exon seven (SMNΔ7), together with two copies of SMN2, further extends lifespan to ~13 days [30–32]. Other models have been created using distinct but comparable strategies [33]. Nevertheless, the SMNΔ7 model has been the most widely utilized for evaluation of candidate SMA therapeutics and so we focus on it here. How close is it to the human disease, and how predictive are positive outcomes in this model?

SMA patients exhibit dramatic differential vulnerability of motor units that innervate different muscles. Despite widespread motor neuron loss and flaccid paralysis, SMA patients retain normal eye movements and external sphincter continence and relatively normal facial expressions [34–36]. Additionally, preserved function of the diaphragm in conjunction with degeneration of the intercostal muscles that support the thoracic cavity produces a “bell-shaped chest” that is virtually pathognomonic for SMA [35,37–39]. Using muscle denervation as a quantitative readout for disease progression, SMNΔ7 mice also show a high degree of differential motor unit vulnerability [32]. Moreover, by comparing the SMNΔ7 model with post-mortem samples from Type I SMA patients on a muscle-by-muscle basis, we have shown a remarkable degree of overlap between the mouse and human neuromuscular phenotypes [40,41]. Therefore, despite the severe phenotype of the SMNΔ7 mouse, the exquisite selectivity of the human disease at the neuromuscular level is modeled with very high fidelity.

There is a less perfect match in terms of other aspects of pathology that also affect the lifespan of the mice. For
example, SMNΔ7 mice exhibit cardiac defects [42,43] and distal tissue necrosis [29,44–46] that are not characteristic features of the human condition [34]. It has been suggested that human SMA is a multi-system disorder, including congenital heart disease and vascular perfusion abnormalities [47,48]. However, in the largest study to date, congenital heart defects were observed only in Type 0 SMA with one copy of SMN2, totaling three out of four Type 0 patients that exhibited a prenatal onset of weakness, contractures, and respiratory distress at birth. None of the 61 Type I SMA patients examined had congenital heart defects, with the exception of a very small number of patients with common, minor cardiac anomalies that resolved spontaneously [49]. Two additional studies examining cardiac involvement in approximately 80 SMA patients with Types I, II, and III concluded that heart dysfunction is not a feature of SMA [50,51]. Case studies have reported ulcerations and necrosis in the distal extremities but, to our knowledge, this is limited to four reported patients with clinical descriptions suggesting Type 0 SMA [49,52]. In the two patients that were kept alive on mechanical ventilation for an extended period of time, all lesions resolved without recurrence [52]. We conclude that multi-organ dysfunction, including cardiac and vascular defects, is not a general feature of human SMA. These findings call for caution when interpreting some published data in SMA mice, as therapeutics that rescue the neuromuscular phenotype but do not ameliorate the underlying cardiac pathology may not produce a commensurate improvement in gross phenotype or survival [53], whereas they might be effective in patients. Endpoints based on quantitative evaluation of neuromuscular pathology may be of greater predictive value.
Overall, therefore, the SMNΔ7 model mimics some aspects of SMA pathology with remarkable precision, but also exhibits differences that may be species-specific and need to be taken into account in comparing therapeutic outcomes.

**In which cell types does SMN need to be restored?**

SMA shares a major characteristic with all neurodegenerative disorders: selective degeneration of a limited subset of neurons in response to dysfunction or deletion of a ubiquitously expressed protein, in this case SMN. An abundant literature based on the SMNΔ7 mouse indicates that, although motor neuron dysfunction and degeneration underlie the principal clinical phenotypes, loss of SMN function in other cell types contributes in important ways. Here, we review the effects of reductions in SMN in different cell types.

**Motor neurons**

SMN in humans is characterized by extensive loss of spinal motor neurons [41,54–56], and human induced pluripotent stem cells (iPSC)-derived motor neurons from SMA patients show an intrinsic survival deficit in vitro [57–59]. However, the fact that many motor neuron subpopulations survive intact at end-stage in the SMNΔ7 mouse, perhaps due to its limited lifespan, has led the field to question the contribution of motor neuron death to the overall phenotype. Nevertheless, motor neurons of the median motor column, which innervate the proximal muscles that are most strongly affected in patients, do show significant cell death at early stages in SMNΔ7 mice [41,54]. Therefore, motor neurons in mouse models, as in human patients, are selectively vulnerable to low SMN. One potential explanation is that normal motor neurons express markedly lower levels of full-length SMN from the SMN2 gene than other cell populations in the spinal cord do, due to particularly inefficient splicing of exon seven [60]. The splicing defect is further exacerbated by the depletion of SMN in the SMNΔ7 mouse, generating a negative feedback loop that may underlie some aspects of motor neuron vulnerability [60,61].

Other studies in mice have examined the effect of modulating SMN specifically within motor neurons. Genetic knockdown of SMN in motor neuron progenitors, using Olig2-Cre-driven recombination of mouse Smm on a background of two copies of SMN2, produced an SMA-like phenotype with motor neuron degeneration and neuromuscular weakness [62]. Despite this demonstration of a cell-autonomous requirement for SMN in motor neurons, the phenotype was markedly less severe than in SMNΔ7 mice, which have reduced SMN in all tissues: approximately 70% of mice with SMN selectively depleted in motor neurons survived to 12 months of age, while SMNΔ7 mice, with ubiquitous SMN reduction, survived an average of 13 days [62]. Moreover, the “reverse” experiment, selective restoration of SMN in the motor neurons of SMNΔ7 mice using a Cre-inducible Smm allele under control of the choline acetyltransferase (ChAT) promoter, fully prevented synaptic dysfunction at the neuromuscular junction, but only partially reduced motor neuron death, and had a relatively modest effect on overall neuromuscular phenotype and death [63]. Collectively, these experiments suggest that SMN reduction in cell types other than motor neurons also contribute substantially to the pathogenesis of SMA.

**Other neuronal classes**

The motor circuitry is a critical mediator of the firing, and thus the functional output, of motor neurons. Given the severe impairments in motor behavior in SMA mice, such as an impaired righting reflex as early as P1 in SMNΔ7 mice, the modest changes in motor neuron loss and transmission at the neuromuscular junction are somewhat surprising. Thus, it has been hypothesized that motor circuit dysfunction contributes to the SMA phenotype. Indeed, studies in the SMNΔ7 mice demonstrated a loss of number and function of synapses onto motor neurons that mediate proprioceptive reflexes, which are important for refining the output of the motor system through feedback signals [54,64]. Loss of these afferent synapses precedes motor neuron loss and even occurs in embryonic SMNΔ7 mice, suggesting this is an early pathological event that contributes to functional impairment in SMA [54,65]. Additionally, it has been demonstrated that the SMA phenotype in Drosophila results primarily from dysfunction in the motor circuit, not the motor unit [66]. However, increasing SMN levels within motor neurons (though perhaps also other cell types) in SMNΔ7 mice, and in a more severe inducible SMA mouse, improves electrophysiological deficits and loss of sensory-motor synapses, indicating that low SMN in motor neurons may also contribute to motor circuit dysfunction [53,63]. The H-reflex, which measures motor unit firing in response to the stimulation of proprioceptive Ia afferents, is reportedly absent in many Type I SMA patients [67]. However, the interpretation of these results is complicated by neuromuscular denervation and motor neuron loss, so this merits further investigation. Overall, there are functional consequences of low SMN in multiple elements of the spinal circuitry, but the full extent of the contribution of each cell type to SMA pathogenesis remains to be fully determined, particularly in human patients.
Other neuronal phenotypes have been reported in mouse models of SMA, including loss of corticospinal neurons in the SMNΔ7 mouse and reduced cell proliferation and neurogenesis in the hippocampus in the severe Smn+/−; SMN2+/− mouse [56,68]. More studies are required to determine whether pathology in these and other neuronal cell types is a previously unappreciated aspect of the human disease.

Muscle
Given the close trophic and functional interactions between motor neurons and the muscles they innervate, much work has been performed to delineate the potential contribution of intrinsic skeletal muscle abnormalities to the SMA phenotype. Early co-culture experiments indicated that extracts of muscle biopsies from SMA patients, but not aged-matched controls, inhibited the trophic effect of neonatal chick muscle on embryonic chick spinal neurons [69]. A later study found that myofibers formed by fused muscle satellite cells from severely affected SMA patients degenerated within 3 weeks of innervation by rodent spinal cord explants, whereas myofibers from mildly affected SMA patients or controls survived for several months [70]. Cultures of SMA satellite cells from severe SMA mice and primary myoblasts from SMNΔ7 mice exhibit an altered expression of MyoD and myogenin, two key muscle developmental factors, and myotube formation deficits [71,72]. Additionally, cultured muscle cells from SMA patient biopsies are smaller than those from control patients and have significantly disrupted expression of myogenic genes critical for muscle development [73,74].

Myofibers in SMNΔ7 mice fail to grow during early postnatal development, producing a severe and uniform reduction in muscle size [75]. These defects may either be muscle-intrinsic or may be secondary to abnormalities in neuromuscular transmission observed even in the presence of fully innervating motor axons [31,76,77]. Moreover, key developmental events at the neuromuscular junction, such as expression of critical myosin isoforms and maturation of the motor endplate, are severely delayed in SMNΔ7 mice [75]. In order to determine the origin of these changes, investigators have modulated SMN expression in SMA mice selectively in muscle.

An early study that increased SMN in muscle did not find significant improvements in motor phenotype or lifespan [78]. However, this study utilized the human skeletal actin (HSA) promoter, which is not expressed in satellite cells or myoblasts. Satellite cells, located between the sarcolemma and basal lamina of muscle fibers, are muscle stem cells responsible for neonatal muscle growth and maintenance and repair of adult muscle; they constitute the major regenerative population in muscles [79,80]. A body of literature has suggested that SMN-deficient satellite cells may contribute to muscle pathology in SMA [70,81–85]. Selective restoration of SMN levels by 50% in muscle satellite cells, on a background of complete Smn deletion in mature myofibers, markedly improved the phenotype, with an extension in median survival from 1 month to approximately 8 months of age [82]. This improvement is likely due to the enormous regenerative capacity of muscle satellite cells. A more recent study selectively restored SMN in early muscle progenitors using the MyoD and Myf5 promoters and found a complete rescue of myofiber growth and an improvement in motor phenotype and survival, but no effect on neuromuscular junction deficits or central synapses. Selective restoration in motor neurons with the ChAT promoter, in contrast, produced only a partial rescue of myofiber growth but restored neuromuscular junction transmission [63]. In conclusion, SMN appears to have cell-autonomous functions in muscle fiber growth and/or maintenance independently of the rest of the motor unit in both human and mouse SMA and may contribute to disease pathogenesis. In particular, SMN in muscle satellite cells appears to be critically important for the regenerative capacity of muscle in response to chronic SMA pathology.

Glial cells
Astrocytes execute critical functions in normal motor neuron physiology, including buffering extracellular ions and neurotransmitters, modulating synaptic structure and function, and the release of neurotrophic factors [86,87]. They also play a pathogenic role in a variety of neurodegenerative diseases, including the motor neuron disease amyotrophic lateral sclerosis (ALS). In preclinical models of familial ALS, astrocytes expressing mutated SOD1 contribute to motor neuron death in a non-cell autonomous manner, likely mediated by the release of a neurotoxic factor [88–91]. This raises the possibility that astrocytes similarly contribute to SMA pathogenesis. Studies using the SMNΔ7 mouse and iPSCs from SMA patients found morphological and cellular changes consistent with activation, including the upregulation of glial fibrillary acidic protein and decreased length of cellular processes [92]. Furthermore, SMA iPSC-derived astrocytes exhibited functional alterations, with an increase in baseline Ca2+ levels and a reduced Ca2+ response to ATP [92]. These changes, which precede motor neuron loss in vivo, indicate that astrocyte dysfunction may contribute to SMA pathology.
Schwann cells around peripheral motor axons form the myelin sheath, which is critical for axonal integrity and fast axon potential conduction [93]. Peripheral nerve abnormalities have been observed in human SMA patients, including reduced conduction velocities, altered membrane conductance, and disruption in myelin [94–97]. It was recently reported that Schwann cells isolated from SMA mice failed to express key myelin proteins during differentiation in vitro, a phenotype that was reversible with restoration of SMN protein. Moreover, defective myelin protein expression and myelination of neurites was observed in co-cultures of SMA-derived Schwann cells and healthy neurons [98]. Alterations in myelination in human and mouse SMA are difficult to interpret, since the motor neurons and their axons also have reduced SMN protein. However, this study raises the intriguing possibility that intrinsic defects in Schwann cells also contribute to SMA pathogenesis.

**Consequences of cell-type specificity for therapeutic strategies based on SMN**

The data above indicate a role for SMN in multiple central nervous system (CNS) cell types related to motor neuron function, or muscles, to which motor units form connections (Figure 2). This implies that, for optimal clinical efficacy, therapeutic restoration of SMN should occur in the whole nervous system and perhaps the periphery (i.e. muscles). Is SMN required in any other peripheral organs, and to what degree is this backed up by preclinical data in the SMNΔ7 mouse?

Increasing SMN levels in the CNS of SMNΔ7 mice with antisense oligonucleotides (ASOs) provides dramatic improvement in the neuromuscular pathology, gross behavior, and lifespan of mice [55,99–104]. Use of morpholino chemistry provides marked rescue of the SMNΔ7 mouse with a single intracerebroventricular (ICV) injection, from ~2 weeks to over 14 weeks [101,102,104]; comparable rescue was achieved using peripheral administration [104]. In contrast, a study using 2′-O-methoxyethyl (MOE) chemistry in another severe SMA mouse model found modest rescue with a single ICV injection but dramatic rescue to over 100 days using high doses peripherally, suggesting that low SMN in peripheral organs contributes significantly to the overall SMA phenotype [100]. This effect was attributed, at least in part, to the correction of an SMN-related decrease in liver production of insulin-like growth factor 1 (IGF-1), which can act as a neurotrophic factor and is important for normal postnatal growth and cardiac development and function [105,106]. However, caution is required when interpreting these studies, since the blood-brain barrier is open during this stage of development and peripheral administration produced substantial increases in full-
length SMN in the CNS [100]. A recent study examined the effect of peripheral administration of IGF-1 with adeno-associated virus (AAV) serotype 1 in severe SMA mice and found improvements in neuromuscular pathology, behavioral deficits, and life span. Unexpectedly, these improvements appeared to result from IGF-1-mediated increases in SMN protein centrally and peripherally [107]. Thus, much of the phenotypic improvement in peripheral versus central administration of MOE oligonucleotides may be due to IGF-1-mediated increases in SMN, further complicating interpretation of the cell type-specific SMN requirements and the implications for human therapy.

The use of AAV vectors, which achieve long-term transgene expression in non-dividing cells, represents another powerful method for restoring SMN in targeted cell types in mouse models of SMA. Indeed, a number of groups have reported dramatic results with self-complementary AAV serotype 9 expressing SMN (scAAV9-SMN), with increases in median survival in SMNΔ7 mice from ~15 days to over 150 days [45,46,108–110]. Peripheral vein or intramuscular scAAV9-SMN administration led to widespread SMN expression in the CNS and periphery, including muscle and liver. Direct CNS injection with scAAV8-SMN, by contrast, appeared to transduce the spinal cord and brain without detectable expression in muscle, although other peripheral organs, such as the liver, were not examined [111]. CNS-restricted SMN expression achieved comparable phenotypic rescue to studies that also transduced peripheral tissue, with an increase in median lifespan from 15 to 157 days [111]. The only study to compare CNS and peripheral administration of scAAV9-SMN found a greater phenotypic rescue in the CNS-injected cohort [110]. However, this study used relatively low titer virus and did not normalize viral dose for route of administration, resulting in significantly lower SMN expression in the spinal cord with peripheral injection. Thus, despite the ability of scAAV8-SMN (and presumably scAAV9-SMN) to selectively target the CNS with intraparenchymal injection, studies to date have not compared these routes of administration in a manner that sheds light on the tissue-specific requirements of SMN restoration.

In conclusion, interpretation of studies using ASOs and AAV vectors to determine the potential contribution of low SMN in the periphery to the SMA phenotype are complicated by a number of factors. Different ASOs have different chemistries (morpholino versus MOE) and the central versus peripheral biodistribution is difficult to predict, especially considering the relative immaturity of the blood-brain barrier in neonatal mice. Moreover, the finding that increasing SMN in the
periphery, specifically the liver, may lead to IGF-1-mediated increases in SMN both peripherally and centrally, complicates delineation of a possible SMN-independent contribution of the liver and IGF-1 signaling to SMA pathogenesis [107]. Moreover, as discussed previously, there are deficits in SMA mouse models that are not present in human patients. Thus, the organ-specific and cell type-specific requirements for SMN require more study before the cellular basis of the benefits of restoration of SMN can be fully defined.

**Therapeutic targets other than SMN and the role of regenerative medicine**

There is rightly much excitement about the ongoing and anticipated trials of SMN-restoring drugs in patients. If the results reflect those obtained using mouse models, they will provide significant benefit for patients. Nevertheless, given general problems in transitioning from mouse to man, as well as specific challenges linked to the stage of SMA at which each agent can be used, it seems reasonable to plan complementary strategies in parallel.
These fall into three main categories: (a) drugs that target molecular or cellular elements of the disease pathway downstream of SMN reduction; (b) neuroprotective treatments that, independently of the disease mechanism, prevent or slow further motor unit loss; and (c) approaches to enhance regeneration of a neuromuscular system that is stabilized but functioning at suboptimal strength.

**Downstream therapeutic targets**

Recent studies have identified molecular steps in the downstream pathway, or candidate modifier genes, that extend survival in SMA mice and are of potential interest [112–121]. However, it remains to be demonstrated that modulation of any of these candidate therapeutic targets can provide protection in the SMNΔ7 mouse comparable with that of SMN restoration. Since the only molecularly defined role for SMN is the biogenesis and assembly of small nuclear ribonucleoproteins (snRNPs), the major component of the spliceosome, it has been hypothesized that deleterious splicing changes initiate the disease process. However, early widespread splicing changes in motor neurons are not a feature of SMA, suggesting that splicing changes in a small number of genes critical for motor unit health induce key pathological processes [122,123]. It was previously shown that SMN reduction alters the snRNP profile in a non-uniform manner, with a preferential reduction of minor snRNPs [124]. Intriguingly, Lotti et al. [125] demonstrated that SMN reduction induces defective splicing and reduces the expression of a discrete set of U12 intron-containing genes in *Drosophila* and mammalian cells. One of these SMN target genes, stasimon, is required for normal neurotransmitter release in *Drosophila* and axon outgrowth in zebrafish [66,125]. Restoration of stasimon in SMN-deficient *Drosophila* corrects some of the neuromuscular junction defects, but not all. Defective splicing and reduced levels of stasimon were also observed in motor neurons in SMA mice. This is the first demonstration of a direct link between SMN reduction, a splicing defect, and specific aspects of the SMA phenotype, supporting the hypothesis that SMA pathogenesis may result from splicing defects in a small number of genes. It will be intriguing to determine whether restoration of normal stasimon levels can rescue the phenotype of the SMNΔ7 mouse and, in the future perhaps, human patients.

**Neuroprotection**

Another potential therapeutic approach is to prevent or delay motor neuron death and degeneration. However, as discussed above, this aspect of the human pathology is underrepresented in the SMNΔ7 model, and it has been argued that such neuroprotective strategies might intervene too late in the disease pathway to be clinically relevant and/or may be ineffective if restricted to motor neurons. A recent preliminary report of a successful Phase 2/3 trial of olesoxime (TRO19622) in SMA patients is potentially exciting in this context. Olesoxime delayed the loss of motor function for 2 years in Type II and non-ambulatory Type III patients in a double-blind, placebo-controlled trial involving 165 patients at 22 sites in seven European countries [126]. Olesoxime was identified by high-throughput screening as a neuroprotective agent for motor neurons *in vitro* [127]. It binds two components of the mitochondrial permeability transition pore—voltage-gated anion channel (VDAC) and translocator protein (TSPO)—and thereby prevents cytochrome c efflux in conditions that would otherwise promote apoptosis [127]. While it is possible that olesoxime may also act through other mechanisms in patients, the most parsimonious conclusion is that neuroprotective strategies have real potential to block progression—though not to provide a complete cure—in patients with SMA.

**Regenerative medicine approaches to neurodegenerative disease**

Patients treated with olesoxime—and even potentially those who undergo SMN-restorative treatments—may experience slowed functional loss but not a complete restoration of muscle strength. In this context, it seems important to consider regenerative therapies that augment the function of the remaining motor units. Therapeutic strategies include enhancing axonal regeneration or sprouting, inducing the hypertrophy of remaining muscle fibers [128–131], or replacing myofibers that have degenerated by the grafting of muscle satellite cells or stem cell-derived skeletal myocytes [70,81–85].

Motor units have substantial capacity for collateral sprouting to re-innervate denervated myofibers, which is an important compensatory mechanism in chronic neuromuscular disease [132–134]. The difficulty of measuring changes in motor unit size due to collateral sprouting in preclinical models of SMA has precluded the assessment of this therapeutic strategy. However, progress has been made in adapting electrophysiological measurements, such as the compound muscle action potential (CMAP), the summated electrical activity of all motor units supplying an individual muscle, and motor unit number estimation (MUNE), a measurement of both motor unit number and size based on CMAP, to mouse models of SMA [135]. CMAP and MUNE have been examined in SMA patients, and are known to correlate with age, SMN2 copy number, and motor function [136,137]. Similar to human patients, CMAP and MUNE measurements of the sciatic nerve in SMNΔ7 mice exhibit preserved neuromuscular function in the early postnatal
Encouragingly, key phenotypes of the mouse models mimic the selective neuromuscular degeneration that characterizes SMA. Although many hurdles remain to be cleared, the decision by NINDS (National Institute of Neurological Disorders and Stroke) in 2003 to identify SMA as the neurological disease most promising for rational therapeutic approaches through the establishment of the SMA Project is looking more and more justified.

Regeneration of myofibers, in parallel with collateral sprouting, is one critical determinant of the adaptive capacity of the neuromuscular system. Given the growing body of evidence that implicates impaired satellite cell regenerative capacity in SMA pathology [82], enhancing muscle regeneration through satellite cell transplantation could provide therapeutic benefit. However, there are not sufficient data to quantitatively evaluate such an approach in SMA mice, given that local muscle transplantation may not lead to functional improvement. Moreover, systematic delivery of satellite cells or stem cell-derived skeletal myocytes to the neuromuscular system of SMA patients presents a considerable therapeutic hurdle.

In addition to increasing myofiber number, enhancing the strength of functional myofibers through hypertrophy represents another potential therapeutic strategy, which has been evaluated by the modulation of myostatin and other pathways that regulate myofiber growth. However, these treatments may not alone be sufficient to prevent progression and may need to be tested together with a disease-stabilizing agent. Administration or transgenic overexpression of the myostatin inhibitor follistatin in SMNΔ7 mice, for example, modestly increased muscle mass, but had modest [130] or no [131] effect on motor function and survival.

Many challenges remain in validating and developing these regenerative medicine approaches to SMA. However, the applicability of these strategies goes well beyond SMA and they would seem an important strand of any long-term strategy for neurodegenerative disease.

Conclusion
This is an exciting time for SMA patients, families and researchers. Not only are multiple clinical trials based on sound preclinical data completed, underway or planned, we also are rapidly gaining a better understanding of the disease process in both molecular and cellular terms. Encouragingly, key phenotypes of the mouse models—which have a genotype close to that of all patients—mimic the selective neuromuscular degeneration that characterizes SMA. Although many hurdles remain to be cleared, the decision by NINDS (National Institute of Medicine and Rehabilitation) in 2003 to identify SMA as the neurological disease most promising for rational therapeutic approaches through the establishment of the SMA Project is looking more and more justified.

Abbreviations
AAV, adeno-associated virus; ALS, amyotrophic lateral sclerosis; ASO, antisense oligonucleotide; ChAT, choline acetyltransferase; CMAP, compound muscle action potential; CNS, central nervous system; ICV, intracerebroventricular; IGF-1, insulin-like growth factor 1; IPSC, induced pluripotent stem cell; MOE, 2'-O-methoxymethyl; MUNE, motor unit number estimation; scAAV, self-complementary AAV; scAAV9-SMN, serotype 9 expressing SMN; snRNP, small nuclear ribonucleoprotein; SMA, spinal muscular atrophy; SMN, survival motor neuron; TSPO, translocator protein; VDAC, voltage-gated anion channel.

Disclosures
Christopher E. Henderson is co-founder and shareholder of the drug discovery biotech Trophos, whose data are reported in references 126 and 127. Trophos is a privately owned French company.

Acknowledgments
We thank our many colleagues in the Motor Neuron Center and the Henderson lab for wide-ranging discussions over the years. Work in the authors’ laboratory on SMA was funded by the SMA Foundation, Association Francaise contre les Myopathies, and NINDS. Justin C. Lee is supported by an NRSA fellowship and the MD-PhD program and Daniel M. Lascone by the Neurobiology and Behavior graduate program. Christopher E. Henderson is a Gurewitsch/Vidda Professor of Rehabilitation and Regenerative Medicine.

References
1. Hoffmann J: Ueber chronische spinale Muskelaatrophiie im Kindesalter, auf familiärer Basis. Deutsche Zeitschrift f Nervenheilkunde 1893, 3:427-70.
2. Hoffmann J: Dritter Beitrag zur Lehre von der hereditären progressiven spinalen Muskelaatrophiie im Kindesalter. Deutsche Zeitschrift f Nervenheilkunde 1900, 10:217-24.
3. Hoffmann J: Weiterer Beitrag zur Lehre von der hereditären progressiven spinalen Muskelaatrophiie im Kindesalter. Deutsche Zeitschrift f Nervenheilkunde 1897, 10:292-320.
4. Werdnig G: Zwei frühinfantile hereditäre Fälle von progressiver Muskelaatrophiie unter dem Bilde der Dystrophie, aber auf neurotischer Grundlage. Archiv f Psychiatry 1891, 22:437-80.
5. Beevor CE: A case of congenital spinal muscular atrophy (family type) and a case of hemorrhage into the spinal cord at birth, giving similar symptoms. Brain 1902, 25:85-108.
6. Sylvestre M: Paralysie flasque de quatre membres et des muscles du tronc (sauf le diaphragme) chez un nouveau-ne. Bull Soc Pediatr Paris 1899, 1:3-10.
motor function and longevity in mice with spinal muscular atrophy. Science (New York, N.Y.) 2014, 345:688-93.

25. Arnold WD, Burghes, Arthur HM: Spinal muscular atrophy: development and implementation of potential treatments. Annals of neurology 2013, 74:348-62.

26. Li DK, Tisdale S, Lotti F, Pellizzoni L: SMN control of RNP assembly: from post-transcriptional gene regulation to motor neuron disease. Seminars in cell & developmental biology 2014, 32:22-9.

27. Schrank B, Goitz R, Gunnersen JM, Ure J, Toyka KV, Smith AG, Sendtner M: Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:9920-5.

28. Monani UR, Sendtner M, Coovert DD, Parsons DW, Andreais C, Le TT, Jablonka S, Schranks B, Rossoli W, Rossoli W, Prior TW, Morris GE; Burghes AH: The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Human molecular genetics 2000, 9:333-9.

29. Hsieh-Li HM, Chang JG, Jong YJ, Wu MH, Wang NM, Tsai CH, Li H: A mouse model for spinal muscular atrophy. Nature genetics 2000, 24:66-70.

30. Le TT, Pham LT, Buttchach, Matthew ER, Zhang HL, Monani UR, Coovert DD, Gavrilina TO, Xing L, Bassell GJ, Burghes, Arthur HM; SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Human molecular genetics 2005, 14:845-57.

31. Kong L, Wang X, Choe DW, Polley M, Burnett BG, Bosars-Marcé M, Griffin JW, Rich MM, Sunner C: Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice. The journal of neuroscience: the official journal of the Society for Neuroscience 2009, 29:842-51.

32. Ling, Karen KY, Gibbs RM, Feng Z, Ko C: Severe neuromuscular denervation of clinically relevant muscles in a mouse model of spinal muscular atrophy. Human molecular genetics 2012, 21:85-95.

33. Monani UR: Spinal muscular atrophy: a deficiency in a ubiquitous protein; a motor neuron-specific disease. Neuron 2003, 48:885-96.

34. Dubowitz V: Muscle disorders in childhood, 2 edn. London: W.B. Saunders; 1995.

35. Byers RK, Banker BQ: Infantile muscular atrophy. Archives of neurology 1961, 5:40-64.

36. Iannaccone ST, Browne RH, Samaha FJ, Buncher CR: Prospective study of spinal muscular atrophy before age 6 years. DCN/ SMA Group. Pediatric neurology 1993, 9:187-93.

37. Kuzuhara S, Chou SM: Localization of the phrenic nucleus in the rat: a HRP study. Neuroscience letters 1980, 6:119-24.

38. Iwata M, Hirano A: "Gial bundles" in the spinal cord late after paralytic anterior poliomyelitis. Annals of neurology 1978, 4:562-3.

39. Shitikhara K, Hara M, Sasaki Y, Misugi K: A neuropathologic study of Werdnig-Hoffmann disease with special reference to the thalamus and posterior roots. Acta neuropathologica 1983, 60:99-106.

40. Lee JC, Papandrea D, Chung WK, Psapia DJ, Goldman JE, CE H: Identifying potential therapeutic targets in SMA through profiling of motor pools that show selective resistance in human patients and mouse models. In: Families of SMA Research Group Meeting; 2013; 2013.
41. Lee JC, Papandreou D, Pisapia DJ, Chung WK, Goldman JE, CE H: Early and selective motor neuron loss as a pathological endpoint for assessing potential therapeutic targets in the SMN3.7 mouse. In: Families of SMA Research Group Meeting: 2014; 2014:14.

42. Shahabi M, Habibii J, Yang HT, Vae SM, Sewell WA, Lorson CL: Cardiac defects contribute to the pathology of spinal muscular atrophy models. Human molecular genetics 2010, 19:4059-71.

43. Heier CR, Satta R, Lutz C, DiDonato CJ: Arrhythmia and cardiac defects are a feature of spinal muscular atrophy model mice. Human molecular genetics 2010, 19:3906-18.

44. Narver HL, Kong L, Burnett BG, Choe DW, Bosch-Marcé M, Taye AA, Erchais MA, Summer CJ: Sustained improvement of spinal muscular atrophy mice treated with trichostatin A plus nutrition. Annals of neurology 2008, 64:465-70.

45. Foust KD, Wang X, McGovern VL, Braun L, Bevan AK, Haidet AM, Azzouz M: Systemic delivery of scAAV9 expressing SMN promotes survival in SMA mouse models. Science translational medicine 2010, 2:13ra42.

46. Hamilton G, Gillingwater TH: Spinal muscular atrophy: going beyond the motor neuron. Trends in molecular medicine 2013, 19:40-50.

47. Shahabi M, Lorson CL, Rudnik-Schöneborn SS: Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease? Journal of anatomy 2014, 224:15-28.

48. Rudnik-Schöneborn S, Helle R, Berg C, Beetzler C, Grimm T, Eggermann T, Eggermann K, Wirth R, Wirth B, Zerres K: Congenital heart disease is a feature of severe infantile spinal muscular atrophy. Journal of medical genetics 2008, 45:353-8.

49. Distefano G, Sciacca P, Parisi MG, Parano E, Smaili P, Marlietta J, Fiumara A: Il coinvolgimento cardiaco nell’atrofia muscolare spinale progressiva. Revisione della letteratura e contributo casistico in età pediatrica. La Pediatra medica e chirurgica: Medical and surgical pediatrics 1994, 16:125-8.

50. Palladino A, Passamano L, Taglia A, D’Ambrosio P, Scudiero M, Cecio MR, Picillo E, Viglione E, Torre V, de Luca F, Nigro G, Pellizzoni L: Cardiac involvement in patients with spinal muscular atrophy. Acta myologica: myopathies and cardiomyopathies: official journal of the Mediterranean Society of Myology / edited by the Goetano Conte Academy for the study of striated muscle diseases 2011, 30:175-8.

51. Araujo, Alexandra prender de Queiroz Campos, Araujo M, Swoboda KJ: Vascular perfusion abnormalities in infants with spinal muscular atrophy. The Journal of Pediatrics 2009, 155:292-4.

52. Gogliotti RG, Quinlan KA, Barlow CB, Heier CR, Heckman CJ, DiDonato CJ: Motor neuron rescue in spinal muscular atrophy mice demonstrates that sensory-motor defects are a consequence, not a cause, of motor neuron dysfunction. The Journal of neuroscience: the official journal of the Society for Neuroscience 2012, 32:3818-29.

53. Mentis GZ, Blivas D, Liu W, Droba E, Crowder ME, Kong L, Alvarez FJ, Sumner CJ, O’Donovan Mj: Early functional impairment of sensory-motor connectivity in a mouse model of spinal muscular atrophy. Neuron 2011, 69:453-67.

54. Passini MA, Bu J, Richards AM, Kinnekom C, Sardi SP, Stanek LM, Hua Y, Rigo F, Matson J, Hung G, Kaye EM, Shihabuddin LS, Krainer AR, Bennett CF, Cheng SH: Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Science translational medicine 2011, 3:127ra184.

55. d’Errico P, Boido M, Piras A, Valsecchi V, Amics E de, Locatelli D, Capra S, Vagni F, Vercelli A, Battaglia G: Selective vulnerability of spinal and cortical motor neuron subpopulations in delta7 SMA mice. PloS one 2013, 8:e62564.

56. Ebert AD, Yu J, Rose FF, Mattis VB, Lorson CL, Thomson JA, Svendsen CN: Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009, 457:277-80.
69. Henderson CE, Hauser SL, Huchet M, Dessi F, Bentati F, Taguchi T, Changeux JP, Fardeau M: Extracts of muscle biopsies from patients with spinal muscular atrophies inhibit neurite outgrowth from spinal neurons. Neurology 1987, 37:1361-4.

70. Braun S, Croizat B, Lagrange MC, Warner JM, Poindron P: Constitutive muscular abnormalities in culture in spinal muscular atrophy. Lancet 1995, 345:694-5.

71. Hayhurst M, Wagner AK, Cerletti M, Wagers AJ, Rubin LL: A cell-autonomous defect in skeletal muscle satellite cells expressing low levels of survival of motor neuron protein. Developmental biology 2012, 368:223-34.

72. Briceno KV, Martinez T, Leikina E, Duguez S, Partridge TA, Henderson CE, Hauser SL, Huchet M, Dessi F, Hentati F, Taguchi T, F1000Prime Reports.

73. Guettier-Sigrist S, Hugel B, Coupin G, Freyssinet J, Poindron P, Warter J: Possible pathogenic role of muscle cell dysfunction in motor neuron death in spinal muscular atrophy. Muscle & nerve 2002, 25:700-8.

74. Boyer LG, Deguise M, Murray LM, Yazdani A, Repentigny Y de, Boudreau-Larivière C, Koehy R: Myogenic program dysregulation is contributory to disease pathogenesis in spinal muscular atrophy. Human molecular genetics 2014, 23:4249-59.

75. Lee YI, Mikesh M, Smith I, Rimer M, Thompson W, Simons M, Trotter J: SMN-dependent intrinsic defects in Schwann cell myelination. Archives of disease in childhood 2011, 96:1063-75.

76. Ruiz R, Casalas JJ, Torres-Benito L, Cano R, Tabares L: Altered intracellular Ca2+ homeostasis in nerve terminals of severe spinal muscular atrophy mice. The Journal of neuroscience: the official journal of the Society for Neuroscience 2010, 30:8489-57.

77. Kariya S, Park G, Maeno-Hikichi Y, Leykooykou Q, Lutz C, Arkovitz MS, Landmesser LT, Manoni UR: Reduced SMN protein deficiency impairs myotube formation by altering myogenic gene expression and focal adhesion dynamics. Human molecular genetics 2014, 23:4745-57.

78. Gavrilina TO, McGovern VL, Workman E, Crawford TO, Gogliotti RG, DiDonato CJ, Manoni UR, Morris GE, Burghes, Arthur HM: Neuronal SMN expression corrects spinal muscular atrophy in severe SMA mice while muscle-specific SMN expression has no phenotypic effect. Human molecular genetics 2008, 17:1063-75.

79. Kiang J, Krauss RS: Muscle stem cells in developmental and regenerative myogenesis. Current opinion in clinical nutrition and metabolic care 2010, 13:243-8.

80. Cerletti M, Shadrach JL, Jurga S, Sherwood R, Wagers AJ: Regeneration and function of skeletal muscle stem cells. Cold Spring Harbor symposium on quantitative biology 2008, 73:317-22.

81. Fidziańska A, Goebel HH, Warlo I: Acute infantile spinal atrophy. Muscle apoptosis as a proposed pathogenic mechanism. Brain: a journal of neurology 1990, 113 (Pt 2): 433-45.

82. Nicole S, Desorges B, Milliet G, Lesbordes J, Cifuentes-Diaz C, Vertes D, Cao ML, Backer F de, Langulle L, Roblot N, Yoshi V, Gillis J, Melki J: Intact satellite cells lead to remarkable protection against Snm gene defect in differentiated skeletal muscle. The Journal of cell biology 2003, 161:571-82.

83. Shafey D, Côté PD, Kohary R: Hypomorphic Smn knockdown C2C12 myoblasts reveal intrinsic defects in myoblast fusion and myotube morphology. Experimental cell research 2005, 311:49-61.

84. Dachs E, Hereu M, Piedrafita L, Casanova A, Calderó J, Esquerra JE: Defective neuromuscular junction organization and postnatal myogenesis in mice with severe spinal muscular atrophy. Journal of neuropathology and experimental neurology 2011, 70:444-61.

85. Mutsaers CA, Wacht MT, Lamont DJ, Riessland M, Schreml J, Howley LH, Murray PM, Parson SH, Lochmüller H, Wirth B, Talbot K, Gillingwater TH: Reversible molecular pathology of skeletal muscle in spinal muscular atrophy. Human molecular genetics 2011, 20:4334-44.

86. Wang DB, Bordey A: The astrocyte odyssey. Progress in neurobiology 2008, 86:342-67.

87. Clarke LE, Barres BA: Emerging roles of astrocytes in neural circuit development. Nature Reviews Neuroscience 2013, 14:311-21.

88. Papadimitriou D, Le Verche V, Jacquier A, Iizki B, Przedborski S, Re DB: Inflammation in ALS and SMA: sorting out the good from the evil. Neurobiology of disease 2010, 37:493-502.

89. Nagi M, Re DB, Nagata T, Chalazonitis A, Jessell TM, Wichterle H, Przedborski S: Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nature neuroscience 2007, 10:165-22.

90. Di Giorgio, Francesco Paolo, Carrasco MA, Siao MC, Maniatis T, Egan K: Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nature neuroscience 2007, 10:608-14.

91. Re DB, Le Verche V, Yu C, Amoroso MW, Politi KA, Phani S, Iizki B, Hoffmann L, Koolen M, Nagata T, Papadimitriou D, Nagy P, Mitsumoto H, Kariya S, Wichterle H, Henderson CE, Przedborski S: Necroptosis drives motor neuron death in models of both sporadic and familial ALS. Neuron 2014, 81:1001-8.

92. McGrew JF, Patiuciu TN, Nord JA, Barbas MA, Stayk CL, Ebers AD: Spinal muscular atrophy astrocytes exhibit abnormal calcium regulation and reduced growth factor production. Glia 2013, 61:1418-28.

93. Simons M, Trotter J: Wrapping it up: the cell biology of myelination. Current opinion in neurobiology 2007, 17:533-40.

94. Chien YY, Nonaka I: Peripheral nerve involvement in Werdnig-Hoffmann disease. Brain & development 1989, 11:221-9.

95. Farrar MA, Vucic S, Lin CS, Park SB, Johnston HM, Du Sart D, Bostock H, Kiernan MC: Dysfunction of axonal membrane conductances in adolescents and young adults with spinal muscular atrophy. Brain: a journal of neuroscience 2011, 134:3185-97.

96. Moosa A, Dubowitz V: Motor nerve conduction velocity in spinal muscular atrophy of childhood. Archives of disease in childhood 1976, 51:974-7.

97. Yonekawa T, Komaki H, Saito Y, Sugai K, Sasaki M: Peripheral nerve abnormalities in pediatric patients with spinal muscular atrophy. Brain & development 2013, 35:165-71.

98. Hunter G, Aghamaley Estarvany A, Roche SL, Symes RC, Gillingwater TH: SMN-dependent intrinsic defects in Schwann cells in mouse models of spinal muscular atrophy. Human molecular genetics 2014, 23:2235-50.

99. Baughan TD, Dickson A, Osman EY, Lorson CL: Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy. Human molecular genetics 2009, 18:1600-11.

100. Hua Y, Sahashi K, Rigo F, Hung G, Horev G, Bennett CF, Krainer AR: Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 2011, 478:123-6.

101. Mitrepan C, Porensky P, Zhou H, Price L, Muntani F, Fletcher S, Wilton SD, Burghes, Arthur HM: Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript.
The GH-IGF-I axis and the cardiovascular system: Model of spinal muscular atrophy. The Journal of clinical investigation 2010, 120:1253-64.

Jorgensen M, Durens M, Xia B, Barlow C, Heier CR, Plasterer HL, Jacobs V, Kiledjian M, Jarecki J, Rusche J, Di Donato CJ: The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models. Human molecular genetics 2013, 22:4084-101.

Kwon DY, Moxley WW, Fischbeck KH, Burnett BG: Increasing expression and decreasing degradation of SMN ameliorate the spinal muscular atrophy phenotype in mice. Human molecular genetics 2011, 20:3667-77.

Van Meerbeke, James P, Gibbs RM, Plasterer HL, Miao W, Feng Z, Lin M, Rucki AA, Wee CD, Xia B, Sharma S, Jacques V, Li DK, Pellizzoni L, Rusche JR, Ko C, Summer CJ: The DcpS inhibitor RG3039 improves motor function in SMA mice. Human molecular genetics 2013, 22:4074-83.

Cherry JJ, Osman EY, Evans MC, Choi S, Xing X, Cuny GD, Glicksman MA, Lorson CL, Androphy EJ: Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compounds. EMBO molecular medicine 2013, 5:1035-50.

Farooq F, Abadía-Molina F, MacKenzie D, Hadwen J, Shamim F, O’Reilly S, Holcik M, MacKenzie A: Celecoxib increases SMN and survival in a severe spinal muscular atrophy mouse model via p38 pathway activation. Human molecular genetics 2013, 22:3415-24.

Gogliotti RG, Cardona H, Singh J, Bail S, Emery C, Kuntz N, Jorgensen M, Durens M, Xia B, Barlow C, Heier CR, Plasterer HL, Jacques V, Kiledjian M, Jarecki J, Rusche J, Di Donato CJ: The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models. Human molecular genetics 2013, 22:4084-101.

Kwon DY, Moxley WW, Fischbeck KH, Burnett BG: Increasing expression and decreasing degradation of SMN ameliorate the spinal muscular atrophy phenotype in mice. Human molecular genetics 2011, 20:3667-77.

Van Meerbeke, James P, Gibbs RM, Plasterer HL, Miao W, Feng Z, Lin M, Rucki AA, Wee CD, Xia B, Sharma S, Jacques V, Li DK, Pellizzoni L, Rusche JR, Ko C, Summer CJ: The DcpS inhibitor RG3039 improves motor function in SMA mice. Human molecular genetics 2013, 22:4074-83.

Cherry JJ, Osman EY, Evans MC, Choi S, Xing X, Cuny GD, Glicksman MA, Lorson CL, Androphy EJ: Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compounds. EMBO molecular medicine 2013, 5:1035-50.

Farooq F, Abadía-Molina F, MacKenzie D, Hadwen J, Shamim F, O’Reilly S, Holcik M, MacKenzie A: Celecoxib increases SMN and survival in a severe spinal muscular atrophy mouse model via p38 pathway activation. Human molecular genetics 2013, 22:3415-24.

Gogliotti RG, Cardona H, Singh J, Bail S, Emery C, Kuntz N, Jorgensen M, Durens M, Xia B, Barlow C, Heier CR, Plasterer HL, Jacques V, Kiledjian M, Jarecki J, Rusche J, Di Donato CJ: The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models. Human molecular genetics 2013, 22:4084-101.

Kwon DY, Moxley WW, Fischbeck KH, Burnett BG: Increasing expression and decreasing degradation of SMN ameliorate the spinal muscular atrophy phenotype in mice. Human molecular genetics 2011, 20:3667-77.

Van Meerbeke, James P, Gibbs RM, Plasterer HL, Miao W, Feng Z, Lin M, Rucki AA, Wee CD, Xia B, Sharma S, Jacques V, Li DK, Pellizzoni L, Rusche JR, Ko C, Summer CJ: The DcpS inhibitor RG3039 improves motor function in SMA mice. Human molecular genetics 2013, 22:4074-83.

Cherry JJ, Osman EY, Evans MC, Choi S, Xing X, Cuny GD, Glicksman MA, Lorson CL, Androphy EJ: Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compounds. EMBO molecular medicine 2013, 5:1035-50.

Farooq F, Abadía-Molina F, MacKenzie D, Hadwen J, Shamim F, O’Reilly S, Holcik M, MacKenzie A: Celecoxib increases SMN and survival in a severe spinal muscular atrophy mouse model via p38 pathway activation. Human molecular genetics 2013, 22:3415-24.

Gogliotti RG, Cardona H, Singh J, Bail S, Emery C, Kuntz N, Jorgensen M, Durens M, Xia B, Barlow C, Heier CR, Plasterer HL, Jacques V, Kiledjian M, Jarecki J, Rusche J, Di Donato CJ: The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models. Human molecular genetics 2013, 22:4084-101.

Kwon DY, Moxley WW, Fischbeck KH, Burnett BG: Increasing expression and decreasing degradation of SMN ameliorate the spinal muscular atrophy phenotype in mice. Human molecular genetics 2011, 20:3667-77.

Van Meerbeke, James P, Gibbs RM, Plasterer HL, Miao W, Feng Z, Lin M, Rucki AA, Wee CD, Xia B, Sharma S, Jacques V, Li DK, Pellizzoni L, Rusche JR, Ko C, Summer CJ: The DcpS inhibitor RG3039 improves motor function in SMA mice. Human molecular genetics 2013, 22:4074-83.

Cherry JJ, Osman EY, Evans MC, Choi S, Xing X, Cuny GD, Glicksman MA, Lorson CL, Androphy EJ: Enhancement of SMN protein levels in a mouse model of spinal muscular atrophy using novel drug-like compounds. EMBO molecular medicine 2013, 5:1035-50.

Farooq F, Abadía-Molina F, MacKenzie D, Hadwen J, Shamim F, O’Reilly S, Holcik M, MacKenzie A: Celecoxib increases SMN and survival in a severe spinal muscular atrophy mouse model via p38 pathway activation. Human molecular genetics 2013, 22:3415-24.

Gogliotti RG, Cardona H, Singh J, Bail S, Emery C, Kuntz N, Jorgensen M, Durens M, Xia B, Barlow C, Heier CR, Plasterer HL, Jacques V, Kiledjian M, Jarecki J, Rusche J, Di Donato CJ: The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models. Human molecular genetics 2013, 22:4084-101.

Kwon DY, Moxley WW, Fischbeck KH, Burnett BG: Increasing expression and decreasing degradation of SMN ameliorate the spinal muscular atrophy phenotype in mice. Human molecular genetics 2011, 20:3667-77.
atrophy. Proceedings of the National Academy of Sciences of the United States of America 2013, 110:19348-53.

124. Gabanella F, Butchbach, Matthew ER, Saieva L, Carissimi C, Burghes, Arthur HM Pellizzoni L: Ribonucleoprotein assembly defects correlate with spinal muscular atrophy severity and preferentially affect a subset of spliceosomal snRNPs. PloS one 2007, 2:e921.

125. Lotti F, Imlach WL, Saieva L, Beck ES, Le Hao T, Li DK, Jiao W, Mentis GZ, Beattie CE, McCabe BD, Pellizzoni L: An SMN-dependent U12 splicing event essential for motor circuit function. Cell 2012, 151:440-54.

126. Dessaud E, Andre C, Scherrer B, Berna P, Pruss R, Cuvier V, Hauke W, SMA Study Investigators, E B: Results of a Phase II study to assess safety and efficacy of olesoxime (TRO19622) in 3-25 year old spinal muscular atrophy patients. In: Families of SMA Research Group Meeting: 2014; 2014.

127. Bordet T, Patrick Berna P, Abitbol JL, RM P: Olesoxime (TRO19622): A Novel Mitochondrial-Targeted Neuroprotective Compound. Pharmaceuticals 2010, 3(2):345-368.

128. Bosch-Marcé M, Wee CD, Martinez TL, Lipkes CE, Choe DW, Kong L, Van Meerbeke, James P, Musarò A, Sumner CJ: Increased IGF-1 in muscle modulates the phenotype of severe SMA mice. Human molecular genetics 2011, 20:1844-53.

129. Rindt H, Buckley DM, Vale SM, Krogman M, Rose FF, Garcia ML, Lorson CL: Transgenic inactivation of murine myostatin does not decrease the severity of disease in a model of Spinal Muscular Atrophy. Neuromuscular disorders: NMD 2012, 22:277-85.

130. Rose FF, Mattis VB, Rindt H, Lorson CL: Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy. Human molecular genetics 2009, 18:997-1005.

131. Sumner CJ, Wee CD, Warsing LC, Choe DW, Ng AS, Lutz C, Wagner KR: Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice. Human molecular genetics 2009, 18:3145-52.

132. Wohlfart G: Collateral regeneration in partially denervated muscles. Neurology 1958, 8:175-80.

133. Brown MC: Sprouting of motor nerves in adult muscles: a recapitulation of ontogeny. Trends in Neurosciences 1984, 7 (1):10-14.

134. McComas AJ, Sica RE, Campbell Mj, Upton AR: Functional compensation in partially denervated muscles. Journal of neurology, neurosurgery, and psychiatry 1971, 34:453-60.

135. Arnold WD, Porensky PN, McGovern VL, Iyer CC, Duque S, Li X, Meyer K, Schmelzer L, Kaspar BK, Kolb SJ, Kissel JT, Burghes, Arthur HM: Electrophysiological Biomarkers in Spinal Muscular Atrophy: Preclinical Proof of Concept. Annals of clinical and translational neurology 2014, 1:34-44.

136. Swoboda KJ, Prior TW, Scott CB, McNaught TP, Wride MC, Reyna SP, Bromberg MB: Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol 2005, 57(5):704-12.

137. Lewelt A, Krosschell KJ, Scott C, Sakonju A, Kissel JT, Crawford TO, Acsadi G, D’anjou G, Elsheikh B, Reyna SP, Schroth MK, Maczulski JA, Stoddard GJ, Elovic E, Swoboda KJ: Compound muscle action potential and motor function in children with spinal muscular atrophy. Muscle & nerve 2010, 42:703-8.